Literature DB >> 19536784

Integrating nine prescription opioid analgesics and/or four signal detection systems to summarize statewide prescription drug abuse in the United States in 2007.

Michael F Schneider1, J Elise Bailey, Theodore J Cicero, Richard C Dart, James A Inciardi, Mark Parrino, Alvaro Muñoz.   

Abstract

PURPOSE: Integrate statewide rankings of abuse across different drugs and/or signal detection systems to summarize prescription drug abuse in each state in 2007.
METHODS: Four signal detection systems (Opioid Treatment Programs, Key Informants, Drug Diversion, and Poison Centers) that covered heterogeneous populations collected data on the abuse of nine opioids: hydrocodone, immediate-release oxycodone, tramadol, extended-release [ER] oxycodone, fentanyl, morphine, methadone, hydromorphone, and buprenorphine). We introduce here linearized maps which integrate nine drugs within each system; four systems for each drug; or all drugs and systems.
RESULTS: When rankings were integrated across drugs, Rhode Island, New Hampshire, Maine, West Virginia, and Michigan were in the highest tertile of abuse in three systems. When rankings were integrated across signal detection systems, there was a geographic clustering of states with the highest rates for ER oxycodone (in Tennessee, Mississippi, Kentucky, Ohio, Indiana, Michigan, and in Massachusetts, New Hampshire, Maine, and Vermont) and methadone (Massachusetts, Rhode Island, New Hampshire, Maine, Vermont, Connecticut, and New Jersey). When rankings were integrated across both drugs and signal detection systems, states with 3-digit ZIP codes below 269 (i.e., from Massachusetts to West Virginia): Massachusetts, New Hampshire, Maine, Vermont, Washington DC, Virginia, and West Virginia were in the highest tertile and only Delaware was in the lowest tertile.
CONCLUSIONS: We have presented methods to integrate data on prescription opioid abuse collected by signal detection systems covering different populations. Linearized maps are effective graphical summaries that depict differences in the level of prescription opioid abuse at the state level.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19536784     DOI: 10.1002/pds.1780

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  16 in total

1.  Overcoming obstacles to developing new analgesics.

Authors:  Clifford J Woolf
Journal:  Nat Med       Date:  2010-10-14       Impact factor: 53.440

2.  Interim treatment: Bridging delays to opioid treatment access.

Authors:  Stacey C Sigmon
Journal:  Prev Med       Date:  2015-04-30       Impact factor: 4.018

3.  Geographic variation in opioid prescribing in the U.S.

Authors:  Douglas C McDonald; Kenneth Carlson; David Izrael
Journal:  J Pain       Date:  2012-10       Impact factor: 5.820

4.  Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment.

Authors:  William W Stoops; Michelle R Lofwall; Paul A Nuzzo; Lori B Craig; Anthony J Siegel; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2012-05-24       Impact factor: 4.530

5.  The ecology of prescription opioid abuse in the USA: geographic variation in patients' use of multiple prescribers ("doctor shopping").

Authors:  Douglas C McDonald; Kenneth E Carlson
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-08-11       Impact factor: 2.890

6.  Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts.

Authors:  Sandra D Comer; Verena E Metz; Ziva D Cooper; William J Kowalczyk; Jermaine D Jones; Maria A Sullivan; Jeanne M Manubay; Suzanne K Vosburg; Mary E Smith; Deena Peyser; Phillip A Saccone
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

7.  Initiation into prescription opioid misuse amongst young injection drug users.

Authors:  Stephen E Lankenau; Michelle Teti; Karol Silva; Jennifer Jackson Bloom; Alex Harocopos; Meghan Treese
Journal:  Int J Drug Policy       Date:  2011-06-20

8.  A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.

Authors:  Stacey C Sigmon; Kelly E Dunn; Kathryn Saulsgiver; Mollie E Patrick; Gary J Badger; Sarah H Heil; John R Brooklyn; Stephen T Higgins
Journal:  JAMA Psychiatry       Date:  2013-12       Impact factor: 21.596

9.  Striatal H3K27 Acetylation Linked to Glutamatergic Gene Dysregulation in Human Heroin Abusers Holds Promise as Therapeutic Target.

Authors:  Gabor Egervari; Joseph Landry; James Callens; John F Fullard; Panos Roussos; Eva Keller; Yasmin L Hurd
Journal:  Biol Psychiatry       Date:  2016-09-28       Impact factor: 13.382

10.  EMS runs for suspected opioid overdose: implications for surveillance and prevention.

Authors:  Amy Knowlton; Brian W Weir; Frank Hazzard; Yngvild Olsen; Junette McWilliams; Julie Fields; Wade Gaasch
Journal:  Prehosp Emerg Care       Date:  2013 Jul-Sep       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.